Evidence map›Paper›PMID 41838426›Full record

ArticleFEBS open bio2026

Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity.

Adriana Cruz, Bruna Abreu, Cindy Mendes, Catarina Freitas-Dias, Filipe Gonçalves, Fernanda Silva, José Ramalho, Saudade André, Vasco D B Bonifácio, Jacinta Serpa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adriana CruziBB-Institute for Bioengineering and Biosciences, and Associate Laboratory i4HB-Institute for Health and Bioeconomy, Instituto Superior Técnico, Lisbon, Portugal.
Bruna AbreuiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal.
Cindy MendesiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal.
Catarina Freitas-DiasiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal.
Filipe GonçalvesInstituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof Lima Basto, Lisbon, 1099-023, Portugal.
Fernanda SilvaiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal.
José RamalhoiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal.
Saudade AndréiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal.
Vasco D B BonifácioiBB-Institute for Bioengineering and Biosciences, and Associate Laboratory i4HB-Institute for Health and Bioeconomy, Instituto Superior Técnico, Lisbon, Portugal.
Jacinta SerpaiNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Lisbon, Portugal.ORCID https://orcid.org/0000-0002-1548-5907

Funding

Fundação para a ciência e a tecnologia (PT) LA/P/0087/2020Fundação para a ciência e a tecnologia (PT) UIDB/04462/2020 UIDP/04462/2020
6 · The paper itself

Abstract

Breast carcinoma (BC) is the most common malignancy in women, with triple-negative breast cancer (TNBC) making up 10-20% of cases. TNBC has limited targeted therapies and poor survival due to late diagnosis and metastasis. Dendrimers are precise nanostructures with a three-dimensional globular architecture designed to target the negatively charged membranes of cancer cells. This study evaluated the anticancer potential of two novel core-shell polycationic polyurea (PURE) dendrimers, PURE

Indexed as

Antineoplastic AgentsDendrimersPolyelectrolytesTriple Negative Breast NeoplasmsAnimalsApoptosisCell Line, TumorFemaleHumansMicePolyaminesPolymersXenograft Model Antitumor AssaysAntineoplastic AgentsDendrimersPolyaminesPolyelectrolytesPolymerspolyureabreast carcinomamembrane‐targeted therapiespolycationic PURE dendrimerstriple‐negative breast carcinoma

Identifiers

PMID41838426
PMCPMC13145356

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.